Clinical trials
Terminated Phase 1/2 trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,976 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 9 |
| 2001 | 10 |
| 2002 | 17 |
| 2003 | 29 |
| 2004 | 30 |
| 2005 | 48 |
| 2006 | 51 |
| 2007 | 76 |
| 2008 | 83 |
| 2009 | 101 |
| 2010 | 83 |
| 2011 | 80 |
| 2012 | 82 |
| 2013 | 80 |
| 2014 | 83 |
| 2015 | 110 |
| 2016 | 85 |
| 2017 | 134 |
| 2018 | 129 |
| 2019 | 119 |
| 2020 | 128 |
| 2021 | 151 |
| 2022 | 113 |
| 2023 | 59 |
| 2024 | 33 |
| 2025 | 22 |
| 2026 | 12 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 1,976 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 58 |
| National Cancer Institute (NCI) | 58 |
| Bristol-Myers Squibb | 23 |
| Pfizer | 21 |
| Incyte Corporation | 20 |
| Shenzhen Geno-Immune Medical Institute | 19 |
| Hoffmann-La Roche | 18 |
| Sanofi | 18 |
| Genmab | 17 |
| Novartis Pharmaceuticals | 16 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 129 |
| Neoplasms | 107 |
| Breast Neoplasms | 104 |
| Leukemia, Myeloid, Acute | 91 |
| Melanoma | 88 |
| Neoplasm Metastasis | 84 |
| Multiple Myeloma | 83 |
| Recurrence | 73 |
| Ovarian Neoplasms | 69 |
| Prostatic Neoplasms | 62 |
Trials
Showing 1 to 25 of 1,976. Each trial links to its page on Pharma Observatory.
1,876 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.